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Abstract Amyotrophic lateral sclerosis (ALS) is a progres-
sive neurodegenerative, clinically heterogeneous syndrome
pathologically overlapping with frontotemporal dementia. To
date, therapeutic trials in animal models have not been able to
predict treatment response in humans, and the revised ALS
Functional Rating Scale, which is based on coarse disability
measures, remains the gold-standard measure of disease pro-
gression. Advances in neuroimaging have enabled mapping of
functional, structural, andmolecular aspects of ALS pathology,
and these objective measures may be uniquely sensitive to the
detection of propagation of pathology in vivo. Abnormalities
are detectable before clinical symptoms develop, offering the
potential for neuroprotective intervention in familial cases.
Although promising neuroimaging biomarker candidates for
diagnosis, prognosis, and disease progression have emerged,
these have been from the study of necessarily select patient
cohorts identified in specialized referral centers. Further mul-
ticenter research is now needed to establish their validity as
therapeutic outcome measures.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease of the motor system and its associated neuronal net-
works. Pathologically it is characterized by cytoplasmic inclu-
sions of ubiquitinated TAR DNA-binding protein 43 in
degenerating upper motor neurons (UMNs) of the primary
motor and frontotemporal cortices, and lower motor neurons
(LMNs) of the brainstem nuclei and spinal cord anterior horns.
The syndrome is heterogeneous and overlaps clinically, path-
ologically, and genetically with frontotemporal dementia
(FTD). Progressive muscle weakness leads eventually to
death, typically caused by respiratory insufficiency, with a
median survival from symptom onset of only 2 to 3 years [1].
ALS is emerging as a final common pathway frommultiple
upstream pathological mechanisms [2]. Approximately 10%
of all cases of ALS are associated with mutations in a single
gene (C9orf72, SOD1, TARDBP, FUS), and asymptomatic
carriers of such mutations offer a window into the earliest
pathological changes [3]. To date, animal models have not
been able to predict treatment response in humans, and there
are no validated biomarkers for human ALS beyond the clin-
ically supported diagnostic application of electromyography,
which is only 60% sensitive. Riluzole, thought to work by
suppressing glutamatergic activity, is the only disease-
modifying treatment for ALS, despite decades of drug trials.
ALS symptoms typically begin in the distal limb or bulbar
musculature, and typically spread to contiguous body regions
clinically [4], outwards from an apparent focus of pathology
in postmortem studies [5]. The diagnosis remains clinical, and
based upon the coincidence of UMN and LMN signs in the
same body regions [6]. The dominance of UMN versus LMN
signs is variable, with extremes of UMN involvement termed
primary lateral sclerosis and those of LMN involvement,
termed progressive muscular atrophy. These extremes are both
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associated with slower rates of progression [7–9]. The clinical,
pathological, and genetic overlap of ALS with FTD is an
adverse prognostic factor [10].
The revised ALS Functional Rating Scale (ALSFRS-R),
which is based on coarse disability measures driven by LMN
dysfunction and remote from histopathological changes, re-
mains the gold-standard measure of disease progression [11,
12]. The incorporation of objective UMNbiomarkers into drug
trials in ALS, such as transcranial magnetic stimulation [13] or
cerebrospinal fluid (CSF) neurofilaments [14], and LMN elec-
trophysiological measures, such as motor unit number estima-
tion [15] and electrical impedance myography [16], have
gained increased attention. As well as improved participant
stratification, they may help to reduce trial length and costs
by providing more objective and sensitive surrogate markers
of slowed disease progression or proof of target engagement.
Histopathological stages of TAR DNA-binding protein 43-
positive pathology based on postmortem ALS brains support
concepts of prion-like connectomic spread of pathology in
ALS [17–19]. Advanced brain imaging techniques such as
magnetic resonance imaging (MRI) and positron emission
tomography (PET) over the last 20 years have bridged the gap
between basic histopathological and molecular science and
in vivo structural and functional abnormalities observed in the
brain and spinal cord [20]. This review will focus on their
potential as surrogate markers for diagnosis, stratification





T1-weighted structural MRI results in images with good tissue
contrast (gray matter, white matter, CSF), and is the method of
choice for the investigation of gray matter, with the added
advantage that the respective sequences are readily available
on clinical MRI scanners. The most basic analysis approach is
to utilize the acquired images in order to outline a region-of-
interest (ROI) known to be affected in a disease process and to
determine the volume of this structure. Conveniently, a number
of currently available analysis tools now allow automated seg-
mentation of various cortical and subcortical brain structures
[21]. These techniques result not only in quantitative volumet-
ric measures, but can also reveal local differences in thickness
and surface shapes of structures and provide cortical thickness
and surface area measures [22]. Automated segmentation tools
help to avoid labor-intensive manual delineation, reduce inter-
rater variability, and usually delineate structures with good
accuracy, although problems can arise in morphometrically
highly unusual brains. In addition to ROI approaches, other
automated postprocessing pipelines such as voxel-based
morphometry (VBM) enable statistics on gray matter density
maps on a whole-brain, voxel-by-voxel basis, and can provide
information on regional atrophy patterns on a group level with-
out the need for a priori assumptions [23, 24].
Derivatives of VBM, such as voxel-based intensitometry
can quantify ALS white matter pathology [25], but the most
commonly applied technique is diffusion tensor imaging
(DTI), which utilizes acquisition sequences sensitive to
Brownian motion of water in fiber bundles [26]. DTI analysis
is based on the observation that the displacement of water
molecules withinwhite matter is approximately elliptical, with
greatest movement along axons, owing to the restrictions in
perpendicular movement imposed by membranes. This be-
havior can be described with a diffusion tensor model, the
mathematical formalism describing the elliptical displacement
profile. The diffusion tensor is typically summarized by mea-
sures such as fractional anisotropy (FA), which describes how
strongly directional the water displacement is within tissue,
and mean diffusivity (MD), which reflects the average dis-
placement distance independent of orientation. Intact white
matter will restrict diffusion parallel to the main fiber direction
(leading to higher FA and lower MD), whereas damage to
white matter will cause diffusivity to be less restricted (i.e.,
lower FA and higher MD) [27]. Furthermore, analysis of di-
rectional diffusivities—parallel axial diffusivity (AD) and
transverse or radial diffusivity (RD)—may provide additional
information on the underlying mechanisms of white matter
integrity loss. However, this simplistic interpretation of diffu-
sion tensor metrics as measures of white matter integrity ne-
glects the fact that diffusion tensor metrics are influenced by a
variety of underlying microstructural causes [28], including
axonal loss, demyelination, and swelling, as well as less or-
derly packing or the presence of multiple fiber populations
(i.e., crossing [29] or Bkissing^ fibers) within a single MRI
voxel. The insufficiency of the diffusion tensor model to de-
scribe fully multiple intravoxel fiber bundles has led to the
development of novel data-acquisition approaches, such as
high angular resolution diffusion imaging and diffusion spec-
trum imaging. Analysis of DTI metrics can be performed
using ROI approaches, or whole-brain voxel-wise methods
such as VBM-style analysis or tract-based spatial statistics
(TBSS) [30]. A further development has been to apply graph
theory to diffusion-weighted MRI data in order to build
models of structural connectivity in brain disorders based on
nodes and edges [31, 32].
Functional MRI
The most common functional MRI (fMRI) technique is based
on the blood oxygen level-dependent (BOLD) response and
the assumption that firing neurons cause locally increased
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energy demands, which result in a local increase of cerebral
blood flow (CBF) and, to a lesser extent, local increases in
cerebral oxygen metabolism and cerebral blood volume, in a
way that creates a relative abundance of oxygenated hemoglo-
bin in that area. Oxygenated and deoxygenated hemoglobin
have different magnetic properties, which makes a change in
their relative quantities detectable byMRI. Given enough rep-
etitions of a task (e.g., an action or thought) performed in the
scanner contrasted with rest periods, statistical methods can be
used to determine the areas in the brain in which MR signal
variations fluctuate in accordance with the task (task-based
fMRI). A more recent development called resting-state fMRI
enables the investigation of the coherence of regional MRI
signals in the brain at rest (i.e., when a patient is not
performing an explicit task). Even in the absence of external
stimuli any brain region will have spontaneous fluctuations in
BOLD signal, allowing the exploration of the brain’s function-
al organization and to investigate deviations from a healthy
pattern in neurological disorders. Resting-state functional
connectivity research has revealed a number of networks
(representing networks of brain regions which show synchro-
nous or coherent activity) that are consistently found in
healthy subjects [33], and bear resemblance to networks
shown to be involved in certain categories of tasks as revealed
by task-based fMRI [34]. The 2 most popular methods for the
analysis of resting state fMRI data are seed-based and inde-
pendent component analysis (ICA). During seed-based analy-
sis, data from a priori-defined voxels or ROI are used to calcu-
late signal correlations with other voxels in the brain. This
hypothesis-driven approach depends on a consistent way to
define the seed within and between patients [35]. ICA, howev-
er, is a data-driven approach, which separates signal into non-
overlapping spatial components (i.e., networks of brain regions)
according to their time courses. ICA-based approaches have the
advantage of being fully automated and mostly observer-
independent [36, 37]. However, data decomposition can slight-
ly vary between runs and resulting components can be difficult
to interpret and may not always clearly relate to brain structures
of interest in a particular research context.
Magnetic Resonance Spectroscopy
Magnetic resonance spectroscopy (MRS) is a means to ex-
plore the metabolite content of brain tissue in vivo. The proton
is the nucleus with the highest nuclear magnetic resonance
sensitivity and natural abundance in living tissue (>99.9 %).
Proton MRS can robustly distinguish N-acetyl aspartate
(NAA; a marker of neuronal integrity), choline (Cho; a marker
of membrane integrity), and creatine (Cr; a chemical involved
in energy metabolism). Furthermore, glutamate-related me-
tabolites (glutamate and glutamine), as well as γ-amino bu-
tyric acid (GABA) can, depending on variables such as mag-
netic field strength, field homogeneity, and signal-to-noise
ratio, be quantified separately or as a composite of glutamate,
glutamine, GABA, and other metabolites in the brain.
PET
PET is used to observe molecular metabolic processes in the
brain using positron emitting radioisotopes (tracers) produced
by a cyclotron. The tracer, injected peripherally, reaches the
brain via a peripheral circulation injection. Subsequently, de-
tectors in the PET scanner record simultaneous 180-degree
pairs of gamma rays emitted as a consequence of positron-
electron-annihilation, allowing 3-dimensional images that in-
dicate the original radiotracer distribution in the brain to be
reconstructed by computer analysis.
Activation PET
The most commonly used metabolic PET tracer for activation
studies is 18F-fluorodeoxyglucose. Similar to fMRI studies,
PET brain activation studies are based on the assumption that
areas of high radioactivity are related to increased blood flow
or, in this case glucose metabolism, and therefore surrogates
for altered regional brain activity.
Ligand PET
Ligand PETallows visualization of neuroreceptor pools in the
brain. For this purpose, tracers have been developed that are
ligands for specific neuroreceptors. These may be expressed
on neurons and so act as surrogates for neuronal loss, or reflect
changes in neurotransmitter levels [38]. Another target has
been benzodiazepine receptors expressed by microglia under-
going change from a resting phenotype to an activated pheno-
type in response to a wide variety of central nervous system
insults, including ALS [39].
Emerging Imaging Biomarkers in ALS
Imaging for Diagnosis and Identification of Drug Targets
White Matter
The diagnostic delay in ALS (on average 1 year from symp-
tom onset) is multifactorial and would not be completely ad-
dressed by the development of a diagnostic biomarker [40].
The detection of occult UMN involvement in clinically LMN-
only cases might, however, increase trial recruitment [41].
DTI metrics have consistently demonstrated significant white
matter alterations in the corticospinal tracts (CSTs) in ALS
compared with healthy controls, reporting reduced FA
[42–50] and increased MD and RD [51, 52]. DTI studies have
specifically noted altered indices in the corpus callosum in
Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis 13
ALS [53–55], as well extensive extramotor white matter in-
volvement [56–58]. Asymptomatic carriers of pathogenic mu-
tations in SOD1 were also reported to have lower FA in the
CSTs [59], though a result not replicated in a subsequent
study [60]. Despite a consistently strong ALS DTI signa-
ture on the group level, a meta-analysis of CST FA mea-
sures revealed its diagnostic power to be modest even
for the differentiation from healthy individuals, with a
pooled sensitivity of 0.68 and a pooled specificity of 0.73
[61]. However, the heterogeneity of both the methodology
and clinical phenotype of participants (especially cognitive
impairment) may have been important factors.
Gray Matter
Compared with imaging measures reflecting white matter
structural integrity, results of cross-sectional VBM studies in
ALS have been somewhat inconclusive. Some studies have
reported gray matter differences between patients and healthy
controls (see, e.g., [50, 62, 63]), while others failed to demon-
strate gray matter abnormalities (see, e.g., [64, 65]). However,
a recent voxel-wise meta-analysis integrated results of 29
VBM studies comprising 638 patients with ALS and 622
healthy controls, to determine consistent gray matter abnor-
malities in ALS [66], and revealed disease-related atrophy
mainly in the right precentral gyrus, the left Rolandic opercu-
lum, the left lenticular nucleus, and the right anterior cingulate
and paracingulate gyri, in keeping with ALS as a pathological
process extending beyond the motor system, even in the ab-
sence of overt cognitive deficits. Similarly, cortical thickness
analyses have consistently revealed thinning of the precentral
gyrus [67–69]. An initial study of the diagnostic performance
of cortical thickness measurement alone against LMN disease
mimics was, however, disappointing [70], but the combina-
tion of measures, either multimodal MRI [61, 71], or MRI and
CSF measures [72], may be a strategy to improve accuracy.
Significant presymptomatic structural changes were also
noted in carriers of C9orf72 hexanucleotide expansions,
linked to the development of ALS and FTD [73, 74].
fMRI
In addition to structural abnormalities, fMRI studies have
demonstrated increased cortical activity in patients with ALS
performing motor tasks [75, 76], as well as aberrations in the
BOLD response to cognitive tasks, such as antisaccade [77] or
phonemic fluency tasks [78]. A number of fMRI studies in-
vestigating differences between patients with ALS and con-
trols at rest have furthermore revealed functional connectivity
abnormalities within the sensorimotor network, although
some studies reported reduced functional connectivity in
ALS [79–81], others increased motor network coherence
[71, 82], and others a mixed picture [83, 84]. These
inconsistencies are most likely driven by methodological dif-
ferences and/or clinical and cognitive heterogeneity of patient
samples. A graph theory, network approach to combined
structural and function MRI datasets suggests that the 2 pro-
cesses are coupled in ALS [85].
A shared signature of resting state functional connectivity
changes involving the cerebellum was noted in both symp-
tomatic sporadic patients and asymptomatic carriers of ALS-
causing genetic mutations [86]. Replication of these findings
in larger cohorts may reveal if functional connectivity changes
are among the earliest detectable brain abnormalities in ALS.
PET
Preceding the wide availability of fMRI, the earliest activation
PET studies also demonstrated widespread abnormalities of
cerebral glucose metabolism [87] and changes in motor task-
induced activation in ALS [88]. Additionally, ligand PET has
provided in vivo evidence for activated microglia in ALS in
motor and frontal lobe regions [89, 90], widespread reductions
in flumazenil binding [91] in keeping with loss of inhibitory
neuronal influences [92], and profoundly reduced binding of a
ligand with serotonin receptor affinity in frontotemporal re-
gions [93], also seen in FTD [94]. An emerging group of
radiotracers targeting glutamate receptors holds particular
promise for exploring the role of excitotoxic mechanisms in
ALS pathogenesis [95], with evidence from the transgenic
mouse model [96].
To date there have been no longitudinal PET studies in
ALS.
MRS
Investigations of metabolic tissue content by means of MRS
have consistently revealed NAA [97, 98] and GABA reduc-
tions in the primary motor cortex in ALS [99], as well as
glutamate and glutamine increases in the brainstem [100].
Methodological variability continues to limit the wider diag-
nostic application of MRS.
Imaging for Stratification
Several studies reported regional gray and white matter chang-
es in relation to clinical and neuropsychological features, most
commonly in relation to site of onset (limb vs bulbar), which is
a well-established prognostic marker [101]. Investigation of
VBM and TBSS correlates in a relatively large cohort of pa-
tients with sporadic ALS revealed that a higher burden of
UMN involvement clinically was associated with a significant
decrease of FA in the CSTs with co-localized increases in AD,
as well as an increase of MD and RD in the CSTs, superior
longitudinal fascicles, and in the corpus callosum [50], partic-
ularly in those with predominant UMN involvement [55, 102,
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103]. Furthermore, surface-based analysis of the precentral
gyrus revealed that compared with patients with ALS, patients
with a UMN phenotype displayed reduced cortical thickness
[70]. The involvement of extramotor cortical regions is more
severe in patients with ALS with cognitive impairment and
ALS-FTD [58].
InvestigatingMRI correlates of ALSFRS subscores in more
detail, lower limb subscore correlated negatively with MD in
the right CST, while VBM-based gray matter volume within
the left primary motor cortex [50], as well as cortical thickness
of corresponding body regions of the motor homunculus [70],
were shown to be correlated with bulbar disability subscore. In
addition, another study found bulbar-onset ALS to be associ-
ated with greater central white matter degeneration than limb-
onset ALS [104]. VBM analysis has also revealed negative
correlations between progression rate and left primary motor
cortex volume [50], while TBSS analysis consistently demon-
strated correlation of CST FAwith progression rate [105].
While these cross-sectional findings suggest that there may
be a range of neuroimaging marker signatures linked to dif-
ferent ALS phenotypes, imaging markers at present do not
appear to offer added value to clinical assessment for the strat-
ification of patients with ALS in the context of a clinical trial.
Imaging Biomarkers of Disease Progression
Structural MRI Changes
Relatively few longitudinal MRI studies have been conducted
in ALS (Table 1). Inconsistencies seem likely to reflect patient
heterogeneity and variable interval between scans
(compounded by small group sizes in some cases), plus differ-
ences in MRI acquisition and analysis protocols. Six published
longitudinal studies focused solely on DTI changes over time.
Two reported no DTI changes in the brain associated with dis-
ease progression (in both cases, DTI data was acquired at 1.5
T). One of these negative studies assessed changes in FA and
MD along the CST using a ROI approach in 11 patients with
ALS and 11 controls at 2 time points that were in some cases
more than 6 months apart (intervals were variable, though
matched between the 2 groups).WhilemeanALSFRS-R scores
in the patient group changed significantly between examina-
tions, UMN burden score remained qualitatively stable, and
neither FA nor MD changed significantly over time [106].
The second study that reported negative results assessed
cross-sectional area, FA and MD of the cervical cord, as well
as CSTaverage FA andMD in 17 patients with ALS at baseline
and after a mean interval of 9 months. While all examined
spinal cord metrics changed significantly, CST measures
remained stable over time in patients with ALS [107]. The
positive spinal cord results were in line with another more re-
cent longitudinal study in which 14 patients underwent 2 MRI
scans approximately 11months apart [108]. At both time points
the cross-sectional area of the cervical and upper thoracic spinal
cord was measured, as well as FA, axial/radial/mean diffusiv-
ities, and magnetization transfer ratio within the lateral CST in
the cervical region [108]. Cross-sectional area and magnetiza-
tion transfer ratio changed significantly between baseline and
follow-up, and the cross-sectional area rate of change was high-
ly correlated upper limb ALSFRS-R subscore rate of change.
Four longitudinal DTI studies suggested cerebral DTI met-
rics to be sensitive to disease progression in ALS [49, 105,
109–111]. A combined 3-T diffusion tensor tractography of
the CST and whole-brain voxel-based analysis of FA maps
was used to investigate the sensitivity of these techniques to
detect white matter changes in 16 patients after 6 months
[49]. FA averaged across both CSTs was found to have signif-
icantly decreased only in the subset of limb-onset ALS.
Looking at more detailed FA profiles along the CST between
the 2 time points they found that in bulbar-onset ALS, FA
decreased significantly over time in the cerebral peduncle/
caudal part of the posterior limb of the internal capsule and in
the subcortical white matter, while in limb-onset ALS, FA de-
creased significantly over time in the medulla oblongata, cere-
bral peduncle/caudal part of the posterior limb of the internal
capsule, and in the subcortical white matter. Additionally, a
whole-brain voxel-wise comparison of baseline and follow-up
FA maps revealed extensive FA reduction in patients with bul-
bar onset of symptoms, comprising the white matter underneath
the primary motor and sensory cortex, premotor cortex, inferior
frontal gyrus, and dorsolateral prefrontal cortex, as well as the
body and genu of the corpus callosum, the left thalamus, the
hippocampal formations, and the right cingulum. In patients
with limb-onset ALS, FA reduction over time was found
throughout the CST, in the body of the corpus callosum, in
the white matter underneath primary sensory cortex and anteri-
or temporal pole, the right thalamus, and cingulum, as well as
the left optic radiations. Reassuringly, none of the reported
analysis approaches revealed any FA changes over time in 11
control subjects that were included in this study.
In a similar study, 3-T tractography of the CST to guide
ROI analysis, as well as voxel-wise analysis, was used to
assess FA and MD changes in 17 patients with ALS over an
average interval of 8 months [110], with a significant decrease
of FA, but not MD, in the right superior CST. This finding was
corroborated by results of the whole-brain voxel-wise analy-
sis. In another 1.5-T voxel-wise study, FA and apparent diffu-
sion coefficient in 15 patients with ALS followed up after 6
months found FA reductions in the CST, frontal areas, and in
the cerebellum, but with an associated nonsignificant average
ALSFRS-R decline [111]. Using tract-based spatial statistics
of FA and MD, as well as RD and AD metrics at 3 T in 19
patients, demonstrated a significant increase in AD in the
posterior limb of the left internal capsule after a 6-month
interval [105]. No FA, MD, or RD changes over time were
detected in this study.
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A graph theory, network approach to diffusion-weighted
data was used with a group of patients with ALS studied twice
with an interval of 5.5 months. This demonstrated an
expanding disintegration of frontal and parietal connections
to the primary motor cortex, supporting the spread of ALS
pathology via structural connections [112]. This type of anal-
ysis is not yet quantifiable to an extent that would be mean-
ingful in the context of a therapeutic trial.
Four published longitudinal MRI studies focused solely on
the assessment of gray matter structural changes in ALS over
time. A tensor-based morphometry study at 1.5 T in 16 pa-
tients and 10 healthy controls investigated ALS-related gray
matter atrophy over an average interval of 9 months [113], and
detected a significant progression of atrophy in the left
premotor cortex and in the right putamen and caudate nucleus.
A surface-based cortical thickness study in 20 patients with
ALS did not find any significant changes over 3 to 10 months
[68]. This negative result was corroborated by a similar study
in a larger cohort of 51 patients with classic ALS, also show-
ing no significant progression of cortical thinning over an
average interval of 8 months [114]. Data for both studies were
acquired at 3 T.
The change in the volume of subcortical gray matter struc-
tures and ventricles in 39 patients with ALS was assessed over
an interval of on average 5.5 months [115], and significant
shrinkage of the right cornu ammonis 2/3 and cornu ammonis
4/dentate gyrus was observed, as well as enlargement of both
lateral, the right inferior lateral, and third and fourth ventricles.
Only 4 studies to date have investigated both white and gray
matter structural decline in the same cohorts. Widespread vol-
ume decreases in gray matter were observed, particularly in the
bilateral frontal and temporal lobes, in a combined VBM and
DTI analysis with 6-month follow-up in 17 patients with ALS
[56]. Additionally, white matter volume reductions and FA and
MD changes were found near CST regions and, most promi-
nently, in the right cerebral peduncles of the midbrain.
Examination of the longitudinal changes of cortical thick-
ness, regional brain volumes, and DTI of the CST and callosum
was undertaken in 9 patients with ALS over an average interval
of 1.26 years [116]. Only those imaging measures that differed
from controls in cross-sectional analyses were used as ROIs for
longitudinal analyses. The results indicated that cortical thinning
and gray matter volume loss of the precentral gyri progressed
between baseline and follow-up. FA of the CSTs remained sta-
ble, but the cross-sectional area declined. Changes in clinical
measures furthermore correlated with changes in precentral cor-
tical thickness and gray matter volume.
In MRI acquired from 27 patients with sporadic ALS at 2
different time points at least 6 months apart [50], TBSS analysis
of DTI data showed only limited significant increases for AD
and MD in a corpus callosum ROI, as well as minor AD in-
creases in the left CST. VBManalysis revealedwidespread gray
matter volume decreases in motor and frontotemporal regions,
the thalami, and caudate heads bilaterally. These findings were
in stark contrast with the results of a subsequent study of 3 time
points over a mean total interval of 6 months in 34 patients with
ALS [117]. While neither VBM, nor cortical thickness analysis
or volumetry of deep gray matter structures indicated progres-
sive gray matter atrophy, FA of the CST showed a significant
linear decline over time but was still less sensitive than the
ALSFRS-R for monitoring disease progression.
MRS
Only 3 MRS studies have investigated changes over time. One
early study acquired structural MRI and multislice 1H MRSI
data in 9 patients, with a minimum of 3 sequential measure-
ments in order to obtain concentrations of NAA, Cre, and Cho
in the left and right motor cortex, and in gray matter and white
matter of nonmotor regions in the brain [118]. For the most
affected motor cortex, NAA/Cre and NAA/(Cre + Cho) ratios
decreased significantly after 1 month. After 3 months, absolute
values of NAA, Cre, and Cho decreased significantly, while the
observed metabolite ratio changes were not significant. For the
least affected motor cortex, no significant changes were found
over 3 months. Furthermore, while NAA, Cre, and Cho con-
centrations decreased over time in the motor cortex, concentra-
tions in nonmotor regions remained qualitatively unchanged.
In a follow-up study by the same group, 13 patients with El
Escorial criteria possible/suspected ALS and 15 patients with
probable/definite ALS received repeated multislice 1H MRSI
scans every 3 months for up to 12 months [119]. While again
the NAA ratios [NAA/Cre, NAA/Cho, and NAA/(Cre+Cho)]
did not show any significant longitudinal change, a decrease in
NAA concentration was observed both within and outside the
motor cortex in the more affected hemisphere only when com-
paring the baseline scan to 3-month follow-up data, but not
beyond. Similarly, Cre and Cho decreases were observed in
the motor cortex of the more affected hemisphere, while in
frontal and parietal nonmotor regions no changes were observed
for Cre at 3 months, but decreases were observed for Cre at 9
months in the more affected hemisphere. Cho decreases were
observed at all time points in the more affected hemisphere
when compared with the initial baseline scan, and in the less
affected hemisphere at both the 6- and 9-month time points.
A third study assessed 1H MRS data of the gray matter of
the motor cortex and the white matter, including the pyramidal
tracts, and investigated concentrations of NAA, Cr, Cho, myo-
inositol, glutamate, and glutamine in 8 patients with definite
ALS at 3 time points (baseline, and after 3 and 6 months)
[120]. In line with the results of the 2 previous studies the
patient group also showed a significant NAA decline in the
motor cortex of both of the clinically more and less affected
hemispheres between first measurement and month 6, as well
as between baseline and month 3 for the less affected side. For
the NAA/(Cr + Cho) ratio, significant decline in the less
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affected hemisphere was observed between baseline and
month 3 and to month 6, as well as from month 3 to month
6. In white matter regions, however, neither NAA nor the
NAA/(Cr + Cho) ratios changed over time.
Taken together these longitudinal imaging findings in ALS
suggest that white-matter pathology may be significantly
established in the symptomatic phase of ALS where therapeu-
tic trials are most likely to take place, with the magnitude of
change likely then greatest in those with the fastest rates of
disease progression.
Neuroimaging Biomarkers Applied to Therapeutic
Trials
Applications in Other Neurodegenerative Disorders
TheAlzheimer’s Disease Neuroimaging Initiative has been piv-
otal in developing the potential of neuroimaging outcome mea-
sures in Alzheimer’s disease therapeutic trials [121]. Significant
challenges remain, particularly in the desire to include function-
al measures in Alzheimer’s disease [122] and now also in
Parkinson’s Disease [123]. MRI was included as an exploratory
surrogate marker in a trial of creatine in those at risk of
Huntington’s disease, in which a treatment-related slowing of
cortical atrophy was demonstrated [124]. Many of the
challenges to the implementation of neuroimaging endpoints
in neurodegenerative disorders, including ALS, are generic.
Limitations of Clinical Measures
Clinical outcome measures in neurodegenerative disorders
generally do not enable the distinction between disease-
modifying and symptomatic drug effects. Symptoms might
temporarily improve under the influence of a drug without a
change in the actual disease activity, which could lead to an
initial overestimation of a potential beneficial drug effect.
Disease-modifying effects might also be missed during the
trial period if they are not immediately reflected in a symp-
tomatic response. Clinical scores are not objective and may be
far removed from the underlying histopathological changes.
They may be influenced by factors not directly disease-related
and cannot be controlled, such as patient motivation and un-
wanted drug side-effects, which can result in reduced statisti-
cal power to detect therapeutic effects and consequently ne-
cessitate larger test cohorts. It has also been noted that rate of
progression as defined by ALSFRS-R in patients seen soon
after symptom onset is less reliable [12], so that neuroimaging
may have a particular value as an objective marker in this
group. Finally, the natural redundancy of biological systems
suggests that clinical symptoms become evident at a relatively
advanced stage of pathology. Clinical scores, by definition,
are not able to assess any neuroprotective therapies applied
to presymptomatic stages.
Power Estimates for the Detection of Therapeutic Effect
Few longitudinal imaging studies in ALS have attempted to
estimate the power of MRI in the detection of therapeutic
effect. Changes of FA rates in the right superior CST were
used to estimate a sample size of 263 patients per arm (placebo
and treatment) to detect a hypothetical treatment effect size of
25% with 80% power [125]. Another study used the signifi-
cant annual rate of change for both ALSFRS-R and FA with
the conclusion that the sample size needed would be 94 pa-
tients per arm for ALSFRS-R versus 567 for FA [117].
Safety and Artifacts
Potential safety risks associated with different brain imaging
methods are an important factor that requires consideration
before application in clinical trials [126]. MRI does not in-
volve ionizing radiation and is generally considered harmless.
However, the strongmagnetic field involved necessitates care-
ful screening for contraindications, as it will attract ferromag-
netic objects and can cause them to move suddenly with great
force. In some cases even nonmagnetic medical implants can
move, and implants, as well as tattoos, can heat substantially
during an MRI scan, potentially causing injury to the exam-
ined patient. Metallic implants, dentures, fillings, permanent
makeup, and so on, can furthermore cause image distortion,
rendering them useless for some analyses. More specific to
ALS, some patients struggle to tolerate long scanning sessions
in a supine position due to joint discomfort, orthopnea, or oral
secretion control. The level of radiation exposure inherent to
PET is relatively low in single study but becomes an addition-
al concern with repeated measurement.
Robustness, Reproducibility, Quantification,
and Harmonization
Before an imaging marker can be proposed as a useful outcome
measure in a clinical trial, the robustness and reproducibility of
the respective technique or analysis method must be evaluated.
While in every imaging study the raw data have to pass some
degree of initial quality control to exclude nondisease-related
gross anatomical abnormalities and artifacts (such as visual in-
spection by an experienced image analyst), some postprocessing
algorithms require higher degrees of data quality than others
in order to be able to run successfully. In research studies,
data are often simply classified as not analyzable and discarded
when a certain algorithm fails. However, this exclusion of data
in the research setting may lead to a biased assessment of the
Breal-world^ usefulness as a biomarker, as an algorithm that
appears to be very sensitive for the detection of disease-related
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abnormalities, but necessitates the exclusion of some data or
subjects, might ultimately require larger test cohorts if used as
an endpoint in a clinical trial.
Another factor is the generalizability of outcomes derived
from research studies that tend to be based in a single imaging
center, often utilizing highly advanced image acquisition hard-
ware and image analysis software and expertise not easily
available in a clinical setting. In contrast, most advanced ther-
apeutic trials are run in a multicenter setting, posing the prob-
lem of combining data from a variety of scanners, potentially
acquired with different imaging sequences that are dictated by
scanner capabilities and limited by hardware constraints.
Usage of multiple scanners, as well as the fact that even on
the same scanner performance is likely to change over time,
necessitates harmonization of data acquisition and analysis
protocols between centers and, most importantly, stringent
quality control. For instance, phantom measurements can be
incorporated to assess both scanner performance and the va-
lidity of postprocessing image corrections in order to reduce
systematic errors in human data [127]. This should, in turn,
increase statistical power for the assessment of brain changes
during therapeutic trials.
It is possible to assess systematic differences across centers
when applying a harmonized acquisition protocol [128], and
then to implement a common database [129]. A feasibility
study involving data from 8 international ALS-specialist clinic
sites, as part of the Neuroimaging Society in ALS (www.
nisals.org), retrospectively combined DTI FA maps of
control participants to establish correction matrices, with
correction algorithms then successfully applied to the FA
maps of the control and ALS patient groups [130]. To
establish a sense of the overall degree of reproducibility of
the imaging metrics of interest and to be able to distinguish
normal intraindividual variability from changes due to ageing,
disease progression, or drug effects, a cohort of healthy
individuals should be scanned repeatedly over a short period
of time at each scanner site. This is particularly important as
even metrics usually labeled as quantitative, such as FA, are
influenced by hardware performance fluctuations. Lastly, care
should be taken to scan an equal number of patients and
controls at each site and close in time, to ensure similar
levels of subject hydration at each scan [131], and use data
preprocessing pipelines that are optimized for longitudinal
analyses and do not introduce biases during intrasubject
image registration [132].
Disease-Specific Effects versus Epiphenomena
An important caveat for the application of fMRI in search of
potential therapeutic targets and markers of disease progres-
sion is that part of the observed differences between patients
and controls, as well as changes over time revealed by imag-
ing in ALS, might simply reflect secondary changes caused by
clinical symptoms. These might be maladaptive or compensa-
tory. Results of ongoing prospective imaging studies in large
cohorts of randomly selected healthy people (e.g.,
http://imaging.ukbiobank.ac.uk), or select individuals with a
high genetic risk of developing ALS in the future that have not
yet developed symptoms (e.g., Pre-fALS study, University of
Miami, FL, USA) may help distinguish disease-related brain
abnormalities from symptom-related changes and identify
neuroprotective targets.
Ageing Confounds
To be able to quantify potential beneficial drug effects on the
brain, the brain changes that occur naturally as the disease
progresses need to be known first. As disease progression
and ageing are invariably correlated, complementary longitu-
dinal brain imaging studies in healthy volunteers are optimal.
Owing to limited resources and ethical considerations (e.g.,
PET studies in healthy individuals), only single time-point
data have generally been acquired for healthy controls in the
research setting.
Drug Effects on Therapeutic Functional Targets versus
Global Effects
While BOLD fMRI has the advantage of being a noninvasive
technique that bypasses some of the safety concerns related to
the use of radioactive substances used in PET, it comes with 1
major limitation that must be considered when interpreting the
BOLD signal, particularly in the context of pharmacological
research. Besides only providing an indirect measurement of
neuronal activity, BOLD fMRI can only detect changes in
blood flow, and does not provide information about the abso-
lute amount of CBF. Consequently, if a drug’s effects on
neurovascular coupling are unknown, a change in the BOLD
signal might not only reflect its influences on neural activity,
but also its potential effects on neuronal signaling to the blood
vessels involved in the CBF response, or on vasculature itself.
Inclusion of healthy volunteers or implementation of comple-
mentary techniques, however, can help to discern neural ac-
tivity and vascular components of the BOLD signal. MR-
based perfusion techniques, such as arterial spin labeling can
be used to obtain quantitative CBF maps either as a single
baseline image or in a time series, in order to control for global
drug-related CBF changes. Arterial spin labeling fMRI is,
however, technically challenging and suffers from poorer
signal-to-noise ratio, and lower spatial and temporal resolution
than BOLD. An alternative approach that can assist interpre-
tation of the BOLD signal is direct quantitative measurement
of neural activation using electrophysiological techniques,
such as electroencephalography or magnetoencephalography
[133, 134]. Both techniques offer excellent temporal resolu-
tion in the millisecond range, but magnetoencephalography
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offers superior spatial resolution with the caveat of currently
being available only in specialist centers.
Conclusions and Future Directions
MRI is unique in being able to assess simultaneously brain
structure and function, and provide a deeper understanding of
in vivo evolution of cerebral pathology as a link between cel-
lular and system dysfunction in ALS. DTI metrics are prom-
ising diagnostic biomarkers, able to identify brain white mat-
ter abnormalities closely linked with known ALS pathology,
and may have a particular niche in the detection of occult
UMN involvement thereby expanding the trial inclusion pool.
Inconsistent findings resulting from longitudinal studies in
ALS can be substantially attributed to small and clinically
heterogeneous groups, and analysis methodology for some
sequences, rather than insensitivity of MRI to structural and
functional cerebral pathology. Ultimately, a multimodal ap-
proach combining imaging, neurophysiology, and biofluid
markers may be needed to provide a signature sensitive
enough to stratify and measure the effect of therapeutics on
disease activity at the level of the individual patient.
Meanwhile, postmortem MRI studies systematically compar-
ing diffusion and other structural imaging metrics with histo-
pathological markers [135] may shed more light on the path-
ological relevance of various MR signals at the histological
level, including emerging hypotheses around spread of pathol-
ogy [136], and so provide equally important mechanistic clues
to guide therapeutic targeting.
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